Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer
Abstract Background We examined real-world outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with apalutamide plus androgen deprivation therapy (ADT). The current study, reflecting real-life practice, included specific subpopulations not evaluated in the pivotal...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14294-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399607131373568 |
|---|---|
| author | Martin Boegemann Mostefa Bennamoun Louis Marie Dourthe Juan Antonio Encarnacion Axel Hegele Eva Hellmis Igor Latorzeff Wolfgang Leicht Julián Oñate-Celdrán Antonio Rosino-Sánchez Krystelle Hanna Joana Lencart Martin Lukac Claudio A. Schioppa Suzy Van Sanden Gero Kramer |
| author_facet | Martin Boegemann Mostefa Bennamoun Louis Marie Dourthe Juan Antonio Encarnacion Axel Hegele Eva Hellmis Igor Latorzeff Wolfgang Leicht Julián Oñate-Celdrán Antonio Rosino-Sánchez Krystelle Hanna Joana Lencart Martin Lukac Claudio A. Schioppa Suzy Van Sanden Gero Kramer |
| author_sort | Martin Boegemann |
| collection | DOAJ |
| description | Abstract Background We examined real-world outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with apalutamide plus androgen deprivation therapy (ADT). The current study, reflecting real-life practice, included specific subpopulations not evaluated in the pivotal phase III TITAN study: patients diagnosed with novel imaging, patients with M1a disease only, and patients treated with concomitant radiotherapy. Methods ArtemisR is the first European multi-country observational study to retrospectively collect data from medical records of patients with mHSPC treated with apalutamide plus ADT in routine clinical practice. Response rates of patients with 50% and 90% decrease in PSA level (PSA50 and PSA90) compared with baseline and undetectable PSA (uPSA, < 0.2 ng/mL) were reported. Time to PSA response, time to metastatic castration-resistant prostate cancer (mCRPC), proportion of apalutamide discontinuation, and survival at 12 months were also examined using the Kaplan–Meier method. Results The analysis included 242 patients from Germany, France, Spain, and Austria; median age was 71 years. Median follow-up was 25.5 months from treatment initiation. Within 12 months of apalutamide initiation, 96% of patients achieved PSA50, 82% achieved PSA90, and 61% achieved uPSA. The median times to PSA50, PSA90, and uPSA were 1.08 months (95% confidence interval [CI]: 0.99–1.28), 1.94 months (95% CI: 1.54–2.27), and 3.48 months (95% CI: 2.92–5.68), respectively. At 12 months after treatment initiation, 94% of patients were alive, 91% had not progressed to mCRPC, and 81% remained on apalutamide plus ADT. Patients diagnosed with novel imaging, patients with M1a disease only, and patients treated with concomitant radiotherapy also showed deep and fast PSA responses (PSA90 and uPSA) with apalutamide plus ADT. Apalutamide-related adverse events (AEs) were reported in 90 patients (37%), and six patients (2.5%) discontinued apalutamide due to AEs. No new safety signals were detected. Conclusions The ArtemisR European multi-centre study examined the efficacy and safety of apalutamide plus ADT for patients with mHSPC, further validating the deep and fast PSA response associated with this treatment regimen. These real-world outcomes were additionally observed in a more diverse patient population than that included in the pivotal TITAN study. |
| format | Article |
| id | doaj-art-4595bed6bd9e4ed08d6f387629cf8a86 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-4595bed6bd9e4ed08d6f387629cf8a862025-08-20T03:38:18ZengBMCBMC Cancer1471-24072025-07-0125111210.1186/s12885-025-14294-7Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancerMartin Boegemann0Mostefa Bennamoun1Louis Marie Dourthe2Juan Antonio Encarnacion3Axel Hegele4Eva Hellmis5Igor Latorzeff6Wolfgang Leicht7Julián Oñate-Celdrán8Antonio Rosino-Sánchez9Krystelle Hanna10Joana Lencart11Martin Lukac12Claudio A. Schioppa13Suzy Van Sanden14Gero Kramer15Department of Urology, University Hospital MünsterOncology Department, Institut Mutualiste MontsourisMedical Oncology, Clinique Sainte-AnneRadio-Oncology, University Hospital Virgen of ArrixacaUrological Center MittelhessenPractice of Urology, Study Center, Urologicum DuisburgClinique Pasteur, Groupe ORIONUrology, Urology Hospital BarmHERZige Brüder RegensburgHospital General Universitario Reina Sofía de MurciaUrology, Hospital General Universitario Morales MeseguerJanssen Pharmaceutica LLC, a, Johnson & Johnson Company, EMEA Medical Affairs Janssen Pharmaceutica LLC, a, Johnson & Johnson Company, EMEA Medical Affairs Parexel International S.R.O. On Behalf of Janssen Pharmaceutica LLC, a Johnson & Johnson Company, Medical AffairsJanssen Pharmaceutica LLC, Johnson & Johnson Company, EMEA Market Access Statistics, Analytics and ModellingJanssen Pharmaceutica LLC, Johnson & Johnson Company, EMEA Market Access Statistics, Analytics and ModellingDepartment of Urology, Comprehensive Cancer Center, Medical University of ViennaAbstract Background We examined real-world outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with apalutamide plus androgen deprivation therapy (ADT). The current study, reflecting real-life practice, included specific subpopulations not evaluated in the pivotal phase III TITAN study: patients diagnosed with novel imaging, patients with M1a disease only, and patients treated with concomitant radiotherapy. Methods ArtemisR is the first European multi-country observational study to retrospectively collect data from medical records of patients with mHSPC treated with apalutamide plus ADT in routine clinical practice. Response rates of patients with 50% and 90% decrease in PSA level (PSA50 and PSA90) compared with baseline and undetectable PSA (uPSA, < 0.2 ng/mL) were reported. Time to PSA response, time to metastatic castration-resistant prostate cancer (mCRPC), proportion of apalutamide discontinuation, and survival at 12 months were also examined using the Kaplan–Meier method. Results The analysis included 242 patients from Germany, France, Spain, and Austria; median age was 71 years. Median follow-up was 25.5 months from treatment initiation. Within 12 months of apalutamide initiation, 96% of patients achieved PSA50, 82% achieved PSA90, and 61% achieved uPSA. The median times to PSA50, PSA90, and uPSA were 1.08 months (95% confidence interval [CI]: 0.99–1.28), 1.94 months (95% CI: 1.54–2.27), and 3.48 months (95% CI: 2.92–5.68), respectively. At 12 months after treatment initiation, 94% of patients were alive, 91% had not progressed to mCRPC, and 81% remained on apalutamide plus ADT. Patients diagnosed with novel imaging, patients with M1a disease only, and patients treated with concomitant radiotherapy also showed deep and fast PSA responses (PSA90 and uPSA) with apalutamide plus ADT. Apalutamide-related adverse events (AEs) were reported in 90 patients (37%), and six patients (2.5%) discontinued apalutamide due to AEs. No new safety signals were detected. Conclusions The ArtemisR European multi-centre study examined the efficacy and safety of apalutamide plus ADT for patients with mHSPC, further validating the deep and fast PSA response associated with this treatment regimen. These real-world outcomes were additionally observed in a more diverse patient population than that included in the pivotal TITAN study.https://doi.org/10.1186/s12885-025-14294-7ApalutamideMetastatic hormone-sensitive prostate cancerProstate-specific antigen |
| spellingShingle | Martin Boegemann Mostefa Bennamoun Louis Marie Dourthe Juan Antonio Encarnacion Axel Hegele Eva Hellmis Igor Latorzeff Wolfgang Leicht Julián Oñate-Celdrán Antonio Rosino-Sánchez Krystelle Hanna Joana Lencart Martin Lukac Claudio A. Schioppa Suzy Van Sanden Gero Kramer Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer BMC Cancer Apalutamide Metastatic hormone-sensitive prostate cancer Prostate-specific antigen |
| title | Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer |
| title_full | Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer |
| title_fullStr | Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer |
| title_full_unstemmed | Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer |
| title_short | Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer |
| title_sort | final analysis of artemisr a european real world retrospective study of apalutamide for the treatment of patients with metastatic hormone sensitive prostate cancer |
| topic | Apalutamide Metastatic hormone-sensitive prostate cancer Prostate-specific antigen |
| url | https://doi.org/10.1186/s12885-025-14294-7 |
| work_keys_str_mv | AT martinboegemann finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT mostefabennamoun finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT louismariedourthe finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT juanantonioencarnacion finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT axelhegele finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT evahellmis finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT igorlatorzeff finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT wolfgangleicht finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT julianonateceldran finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT antoniorosinosanchez finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT krystellehanna finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT joanalencart finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT martinlukac finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT claudioaschioppa finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT suzyvansanden finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer AT gerokramer finalanalysisofartemisraeuropeanrealworldretrospectivestudyofapalutamideforthetreatmentofpatientswithmetastatichormonesensitiveprostatecancer |